NASDAQ:OPHT - Ophthotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.77 -0.10 (-3.48 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$2.89
Today's Range$2.77 - $2.89
52-Week Range$2.24 - $3.60
Volume4,134 shs
Average Volume259,079 shs
Market Capitalization$103.86 million
P/E Ratio0.89
Dividend YieldN/A
Beta1.36

About Ophthotech (NASDAQ:OPHT)

Ophthotech logoOphthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and novel gene delivery technologies to target retinal diseases. The company was founded in 2007 and is based in New York, New York.

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio18.62
Quick Ratio18.62

Price-To-Earnings

Trailing P/E Ratio0.89
Forward P/E Ratio-1.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$209.98 million
Price / Sales0.48
Cash Flow$3.1477 per share
Price / Cash0.88
Book Value$1.06 per share
Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$114.20 million
Net Margins26.69%
Return on Equity-1,485.62%
Return on Assets79.93%

Miscellaneous

Employees38
Outstanding Shares36,190,000

Ophthotech (NASDAQ:OPHT) Frequently Asked Questions

What is Ophthotech's stock symbol?

Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech's earnings last quarter?

Ophthotech (NASDAQ:OPHT) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.04. Ophthotech had a negative return on equity of 1,485.62% and a net margin of 26.69%. View Ophthotech's Earnings History.

When is Ophthotech's next earnings date?

Ophthotech is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Ophthotech.

What price target have analysts set for OPHT?

2 brokerages have issued 1-year price targets for Ophthotech's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ophthotech's stock price to reach $4.00 in the next year. View Analyst Ratings for Ophthotech.

Who are some of Ophthotech's key competitors?

Who are Ophthotech's key executives?

Ophthotech's management team includes the folowing people:
  • Dr. David R. Guyer, Chairman and Chief Exec. Officer (Age 58)
  • Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
  • Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
  • Dr. Michael J. Ross, Director (Age 69)
  • Mr. David F. Carroll M.B.A., CFO & Treasurer (Age 52)

Has Ophthotech been receiving favorable news coverage?

News stories about OPHT stock have trended somewhat positive this week, Accern reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ophthotech earned a news sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Ophthotech's major shareholders?

Ophthotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include Tamarack Advisers LP (2.35%), Dimensional Fund Advisors LP (1.56%), Spark Investment Management LLC (1.18%), Municipal Employees Retirement System of Michigan (1.06%), Millennium Management LLC (0.94%) and GSA Capital Partners LLP (0.62%). Company insiders that own Ophthotech stock include A/S Novo, Axel Bolte, Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Keith Westby and Samir Chandrakant Patel. View Institutional Ownership Trends for Ophthotech.

Which major investors are selling Ophthotech stock?

OPHT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd. and A.R.T. Advisors LLC. Company insiders that have sold Ophthotech company stock in the last year include Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View Insider Buying and Selling for Ophthotech.

Which major investors are buying Ophthotech stock?

OPHT stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Spark Investment Management LLC, Tamarack Advisers LP, Alambic Investment Management L.P. and Northern Trust Corp. View Insider Buying and Selling for Ophthotech.

How do I buy shares of Ophthotech?

Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ophthotech's stock price today?

One share of OPHT stock can currently be purchased for approximately $2.77.

How big of a company is Ophthotech?

Ophthotech has a market capitalization of $103.86 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.

How can I contact Ophthotech?

Ophthotech's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]


MarketBeat Community Rating for Ophthotech (OPHT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ophthotech (NASDAQ:OPHT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Ophthotech in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 44.40%. The high price target for OPHT is $4.00 and the low price target for OPHT is $4.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.501.502.002.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$10.00
Price Target Upside: 44.40% upside31.15% upside43.37% upside258.42% upside

Ophthotech (NASDAQ:OPHT) Consensus Price Target History

Price Target History for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018JPMorgan ChaseDowngradeNeutral ➝ UnderweightLowView Rating Details
9/21/2017Stifel NicolausReiterated RatingHold$4.00LowView Rating Details
12/13/2016GabelliDowngradeBuy ➝ HoldN/AView Rating Details
12/13/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/AView Rating Details
12/12/2016Goldman SachsUpgradeSell ➝ NeutralN/AView Rating Details
12/12/2016Leerink SwannDowngradeOutperform ➝ Market PerformN/AView Rating Details
12/12/2016BTIG ResearchDowngradeBuy ➝ NeutralN/AView Rating Details
12/12/2016CowenDowngradeOutperform ➝ Market PerformN/AView Rating Details
12/12/2016CitigroupDowngradeBuy ➝ NeutralN/AView Rating Details
12/12/2016BarclaysDowngradeOverweight ➝ Equal WeightN/AView Rating Details
12/12/2016SunTrust BanksDowngradeBuy ➝ HoldN/AView Rating Details
12/12/2016Chardan CapitalDowngradeBuy ➝ Neutral$15.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Ophthotech (NASDAQ:OPHT) Earnings History and Estimates Chart

Earnings by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.63 EPS
Next Year EPS Consensus Estimate: $-1.25 EPS

Ophthotech (NASDAQ OPHT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018        
5/9/2018Q1($0.4020)($0.3620)ViewListenView Earnings Details
2/27/2018Q4 2017($0.58)($0.26)$1.00 millionViewListenView Earnings Details
11/8/2017Q3 2017$4.38$5.25$185.00 million$206.65 millionViewN/AView Earnings Details
7/26/2017Q2 2017($1.07)($0.62)$1.38 million$1.66 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.31)($1.20)$1.94 million$1.66 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.64)($1.86)$6.27 million$5.32 millionViewN/AView Earnings Details
11/8/2016Q316($1.64)($1.71)$6.20 million$1.67 millionViewListenView Earnings Details
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ophthotech (NASDAQ:OPHT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ophthotech (NASDAQ OPHT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 58.72%
Insider Trading History for Ophthotech (NASDAQ:OPHT)
Institutional Ownership by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ OPHT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Glenn SblendorioInsiderSell6,838$2.69$18,394.2255,245View SEC Filing  
1/5/2018Barbara A WoodSVPSell602$3.17$1,908.3417,064View SEC Filing  
1/5/2018David R GuyerInsiderSell3,798$3.17$12,039.6642,458View SEC Filing  
1/5/2018Keith WestbyCOOSell317$3.17$1,004.8925,300View SEC Filing  
1/3/2018Keith WestbyCOOSell356$3.24$1,153.4424,956View SEC Filing  
1/2/2018Barbara A WoodSVPSell5,289$3.19$16,871.9120,472View SEC Filing  
1/2/2018David R GuyerInsiderSell16,520$3.19$52,698.8050,494View SEC Filing  
1/2/2018Glenn SblendorioCEOSell8,089$3.19$25,803.9144,584View SEC Filing  
7/5/2017Barbara A WoodSVPSell5,119$2.58$13,207.0213,451View SEC Filing  
7/5/2017David Francis CarrollCFOSell3,284$2.58$8,472.727,500View SEC Filing  
7/5/2017David R GuyerChairmanSell17,678$2.58$45,609.2437,692View SEC Filing  
7/5/2017Glenn SblendorioCEOSell7,828$2.58$20,196.2431,992View SEC Filing  
6/13/2017David E RedlickDirectorSell700$2.52$1,764.001,050View SEC Filing  
4/3/2017Glenn SblendorioCFOSell7,388$3.56$26,301.28View SEC Filing  
1/5/2017David R GuyerCEOSell3,785$4.96$18,773.6010,997View SEC Filing  
1/5/2017Henric Bjorn BjarkeSVPSell316$4.96$1,567.361,700View SEC Filing  
1/5/2017Samir Chandrakant PatelPresidentSell3,844$4.96$19,066.2418,332View SEC Filing  
1/3/2017Barbara A WoodSVPSell675$4.90$3,307.501,375View SEC Filing  
1/3/2017David R GuyerCEOSell3,484$4.90$17,071.608,231View SEC Filing  
1/3/2017Samir Chandrakant PatelPresidentSell2,999$4.90$14,695.1016,406View SEC Filing  
12/23/2016Barbara A. WoodSVPSell746$4.92$3,670.32View SEC Filing  
12/22/2016Glenn SblendorioCFOSell1,079$4.85$5,233.15View SEC Filing  
12/15/2016A/S NovoMajor ShareholderSell3,610,487$4.87$17,583,071.691,405,487View SEC Filing  
11/1/2016David R GuyerCEOSell22,060$35.61$785,556.6024,541View SEC Filing  
10/3/2016David R GuyerCEOSell22,060$44.37$978,802.2024,541View SEC Filing  
9/29/2016Samir Chandrakant PatelPresidentSell20,000$55.17$1,103,400.0024,239View SEC Filing  
8/29/2016Samir Chandrakant PatelPresidentSell20,000$52.80$1,056,000.00View SEC Filing  
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.2056,451View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00176,031View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.2056,451View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58174,992View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.006,000View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.201,750View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.6062,451View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00213,377View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.003,610,489View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.8054,451View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00231,008View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.6054,451View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00248,410View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.8054,451View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00263,736View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00260,911View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.7432,391View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.005,684View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00746View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.2429,910View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00278,605View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24278,605View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.007,684View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.1829,910View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05278,605View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.009,684View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85278,605View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05259,292View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.5829,910View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10259,292View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.1629,910View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25259,292View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.003,139,902View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.1511,891View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55104,472View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.3134,583View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04135,667View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04140,228View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ophthotech (NASDAQ OPHT) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Ophthotech (OPHT) to Post -$0.40 Earnings Per ShareZacks: Brokerages Anticipate Ophthotech (OPHT) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - May 19 at 5:25 AM
Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels ...Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels ...
www.nasdaq.com - May 14 at 5:25 PM
Form DEFA14A Ophthotech Corp.Form DEFA14A Ophthotech Corp.
www.streetinsider.com - May 14 at 5:25 PM
Ophthotech (OPHT) Upgraded by Zacks Investment Research to "Buy"Ophthotech (OPHT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 14 at 12:13 PM
Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - May 14 at 8:18 AM
Ophthotechs (OPHT) Q1 Loss Narrows Y/Y, Zimura in FocusOphthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
www.nasdaq.com - May 10 at 6:05 PM
Edited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMTEdited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:17 AM
Ophthotech (OPHT) Issues Quarterly  Earnings ResultsOphthotech (OPHT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 8:52 PM
Ophthotechs (OPHT) CEO Glenn Sblendorio on Q1 2018 Results - Earnings Call TranscriptOphthotech's (OPHT) CEO Glenn Sblendorio on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:40 PM
Ophthotech Corp (OPHT) Tops Q1 EPS by 4cOphthotech Corp (OPHT) Tops Q1 EPS by 4c
www.streetinsider.com - May 9 at 8:12 AM
Ophthotech Reports First Quarter 2018 Financial and Operating ResultsOphthotech Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 9 at 8:12 AM
Ophthotech: 1Q Earnings SnapshotOphthotech: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:12 AM
Wired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular DegenerationWired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration
finance.yahoo.com - May 3 at 8:09 AM
Ophthotech (OPHT) Scheduled to Post Quarterly Earnings on WednesdayOphthotech (OPHT) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 1:56 PM
BRIEF-Ophthotech Completes Patient Recruitment In A Mid-Stage Trial Of Its Eye Drug ZimuraBRIEF-Ophthotech Completes Patient Recruitment In A Mid-Stage Trial Of Its Eye Drug Zimura
www.reuters.com - May 1 at 8:16 AM
Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of ZimuraOphthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura
www.businesswire.com - May 1 at 8:16 AM
Ophthotech (OPHT) Receives Average Rating of "Hold" from AnalystsOphthotech (OPHT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 5:34 PM
Ophthotech (OPHT) Upgraded to "Buy" at ValuEngineOphthotech (OPHT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM
Ophthotech (OPHT) Given Consensus Recommendation of "Hold" by BrokeragesOphthotech (OPHT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 5:40 PM
Insider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of StockInsider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of Stock
www.americanbankingnews.com - April 3 at 11:04 PM
Ophthotech (OPHT) Rating Lowered to D+ at TheStreetOphthotech (OPHT) Rating Lowered to D+ at TheStreet
www.americanbankingnews.com - March 24 at 12:11 PM
Regeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - NasdaqRegeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - Nasdaq
www.nasdaq.com - March 21 at 8:40 AM
Regeneron Eylea Hits 24-Week Primary Endpoint in StudyRegeneron Eylea Hits 24-Week Primary Endpoint in Study
finance.yahoo.com - March 21 at 8:39 AM
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - BenzingaEeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - Benzinga
www.benzinga.com - March 20 at 8:19 AM
Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co.Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co.
www.americanbankingnews.com - March 19 at 10:59 AM
Ophthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from BrokeragesOphthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 11 at 6:18 PM
Ophthotech (OPHT) Stock Rating Lowered by Zacks Investment ResearchOphthotech (OPHT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 12:49 PM
Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT)Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 2:56 PM
Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT)Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 10:30 AM
Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - March 6 at 8:09 AM
Ophthotech to Present at the Cowen and Company 38th Annual Health Care ConferenceOphthotech to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:09 AM
Ophthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DEOphthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DE
www.americanbankingnews.com - March 6 at 5:04 AM
Ophthotech (OPHT) Downgraded by ValuEngine to HoldOphthotech (OPHT) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - March 4 at 12:48 PM
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release)Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - March 1 at 8:09 AM
Ophthotechs (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOphthotech's (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 1 at 8:09 AM
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - NasdaqOphthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - Nasdaq
www.nasdaq.com - March 1 at 8:09 AM
Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal DiseasesBlog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases
finance.yahoo.com - March 1 at 8:09 AM
Ophthotech (OPHT) Given New $4.00 Price Target at Chardan CapitalOphthotech (OPHT) Given New $4.00 Price Target at Chardan Capital
www.americanbankingnews.com - February 28 at 4:34 PM
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in FocusOphthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
www.zacks.com - February 28 at 8:11 AM
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating ResultsOphthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
finance.yahoo.com - February 27 at 5:59 PM
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease StrategyOphthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy
finance.yahoo.com - February 27 at 5:59 PM
Ophthotech (OPHT) Announces  Earnings Results, Beats Estimates By $0.29 EPSOphthotech (OPHT) Announces Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - February 27 at 9:12 AM
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release)Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release)
www.businesswire.com - February 27 at 8:12 AM
Ophthotech (OPHT) Scheduled to Post Earnings on TuesdayOphthotech (OPHT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 22 at 1:16 PM
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)
www.businesswire.com - February 21 at 8:15 AM
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018
finance.yahoo.com - February 21 at 8:15 AM
Ophthotech Corp (OPHT) Given Average Rating of "Buy" by AnalystsOphthotech Corp (OPHT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 14 at 5:34 PM
Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from BrokeragesOphthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
Ophthotech Begins Phase II Zimura Study in Stargardt DiseaseOphthotech Begins Phase II Zimura Study in Stargardt Disease
www.zacks.com - January 17 at 10:10 AM
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...
www.businesswire.com - January 16 at 4:38 PM

SEC Filings

Ophthotech (NASDAQ:OPHT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ophthotech (NASDAQ:OPHT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ophthotech (NASDAQ OPHT) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.